Biotechs Are a Mosaic of Positive Technicals

10/09/2014 7:00 am EST

Focus: ETFS

Gregory Harmon, CMT

Founder and President, Dragonfly Capital Management

Greg Harmon of Dragonfly Capital looks at the chart of a biotech ETF for a mixture of technicals—each derived from a different history—to determine which of them, if any, signal that the path to the upside may be easier for biotechs.

I know nothing about creating drugs but I assume that I do. I imagine that people with white lab coats and thick rimmed black glasses walk around the lab all day holding beakers, most of which are spewing smoke. They mix this and that together to create a new mosaic drug. Then they put it in a 12-inch long needle and try it out on their subjects who signed up to get paid $30/day as human guinea pigs. Innovation.

Click to Enlarge

This thinking inspired me to look at the chart of the Biotech ETF, (BIB). The chart above is a mixture of technicals. There are three different types of technical analysis shown, each derived from a different history. But each signals that the path may be easier to the upside for Biotechs. First, the yellow Cup and Handle pattern, triggered with a move back over the top of the Cup. This pattern carries a target to 136. Second, the two red lines show an Ascending Triangle. The break above the horizontal one created a target to 136 as well. Next, the two red shaded triangles show a Butterfly harmonic pattern. This has a Potential Reversal Zone at about 124. The price has stalled over the past month, holding over the round number 100 and the breakout levels from the Cup and Handle and Ascending Triangle, but below the prior high at 108. A move over that may lead to continuation higher. All bets are off under the stop, though, around 99.

By Greg Harmon of Dragonfly Capital

  By clicking submit, you agree to our privacy policy & terms of service.

Related Articles on ETFS

Keyword Image
S&P 500 to Test Key Resistance
01/22/2019 1:10 pm EST

Two key resistance levels are lining up this week in the S&P 500, according to Todd Salamone. He...